Ken Griffin Kazia Therapeutics LTD Put Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
17Shares Held
2.09MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$2 Million0.01% of portfolio
-
Ubs Group Ag249KShares$366,6940.0% of portfolio
-
Morgan Stanley New York, NY220KShares$323,7830.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$67,7810.0% of portfolio
-
United Bank Vienna, VA44KShares$64,6800.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $22.2M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...